mTOR inhibitors and calcineurin inhibitors do not affect adhesion molecule expression of human macro- and microvascular endothelial cells

Journal of Vascular Research

Volumn 45, Issue 4, 2008, Pages 333-342

  Lehle, Karla ^a   Schreml, Stephan ^a   Kunz Schughart, Leoni A ^a,b   Rupprecht, Leopold ^a   Birnbaum, Dietrich E ^a   Schmid, Christof ^a   Preuner, Jürgen G ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Adhesion molecules; Calcineurin inhibitors; E selectin; ICAM 1; mTOR inhibitors; VCAM 1

Indexed keywords

CALCINEURIN INHIBITOR; CASPASE 3; CASPASE 7; CELL ADHESION MOLECULE; CYCLOSPORIN A; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; TACROLIMUS; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CORONARY ARTERY; CYTOTOXICITY TEST; DRUG EFFECT; DRUG INHIBITION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAPHENOUS VEIN;

BLOOD VESSELS; CALCINEURIN; CAPILLARIES; CELL ADHESION MOLECULES; CELL PROLIFERATION; CELLS, CULTURED; CYCLOSPORINE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; PROTEIN KINASES; SIROLIMUS; TACROLIMUS;

EID: 44849104570     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000119199     Document Type: Article

References (39)

1. Weis M, von Scheidt W: Cardiac allograft vasculopathy: a review. Circulation 1997;96:2069-2077.
2. Wu YW, Lee CM, Lee YT, Wang SS, Huang PJ: Value of circulating adhesion molecules in assessing cardiac allograft vasculopathy. J Heart Lung Transplant 2003;22:1284-1287.
3. Olyaei AJ, de Mattos AM, Bennett WM: Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001;7:384-389.
4. Weis M, Wildhirt SM, Schulze C, Pehlivanli S, Rieder G, Wolf WP, Wilbert-Lampen U, Meiser BM, Enders G, von Scheidt W: Coronary vasomotor dysfunction in the cariac allograft: impact of different immunosuppressive regimens. J Cardiovasc Pharmacol 2000;36:776-784.
5. Charreau B, Coupel S, Goret F, Pourcel C, Soulillou JP: Association of glucocorticoids and cyclosporin A or rapamycin prevents Eselectin and IL-8 expression during LPSand TNF-mediated endothelial cell activation. Transplantation 2000;69:945-953.
6. Trapp A, Weis M: The impact of immunosuppression on endothelial function. J Cardiovasc Pharmacol 2005;45:81-87.
7. Wilasrusmee C, Da Silva M, Singh B, Siddiqui J, Bruch D, Kittur S, Wilasrusmee S, Kittur DS: Morphological and biochemical effects of immunosuppressive drugs in a capillary tube assay for endothelial dysfunction. Clin Transplant 2003;17:6-12.
8. Aird WC: Spatial and temporal dynamics of the endothelium. J Thromb Haemost 2005;3:1392-1406.
9. Ribatti D, Nico B, Vacca A, Roncali L, Dammacco F: Endothelial cell heterogeneity and organ specificity. J Heamatother Stem Cell Res 2002;11:81-90.
10. Lehle K, Buttstaedt J, Birnbaum DE: Expression of adhesion molecules and cytokines in vitro by endothelial cells seeded on various polymer surfaces coated with titaniumcarboxonitride. J Biomed Mater Res 2003;65:393-401.
11. De Clerck LS, Bridts CH, Mertens AM, Moens MM, Stevens WJ: Use of fluorescent dyes in the determination of adherence of human leucocytes to endothelial cells and the effect of fluorochromes on cellular function. J Immunol Methods 1994;172:115-124.
12. Esposito C, Fornoni A, Cornacchia F, Bellotti N, Fasoli G, Foschi A, Mazzucchelli I, Mazzullo T, Semeraro L, Dal Canton A: Cyclosporine induces different responses in human epithelial, endothelial and fibroblast cell cultures. Kidney Int 2000;58:123-130.
13. Miriuka SG, Rao V, Peterson M, Tumiati L, Delgado DH, Mohan R, Ramzy D, Stewart D, Ross HJ, Waddell TK: mTOR inhibition induces endothelial progenitor cell death. Am J Transplant 2006;6:2069-2079.
14. Mohacsi PJ, Tuller D, Hulliger B, Wijngaard PL: Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 1997;16:484-492.
15. Kochi S, Takanaga H, Matsuo H, Naito M, Tsuruo T, Sawada Y: Effect of cyclosporin A or tacrolimus on the function of blood-brain barrier cells. Eur J Pharmacol 1999;372:287-295.
16. Wu MS, Yu HM, Hong JJ, Lai BC, Huang CC, Vandewalle A: Cyclosporine, but not FK 506 and rapamycin, enhances cell proliferation in mouse medullary thick ascending cultured cells. Transplant Proc 1998;30:3565-3566.
17. Garweg JG, Wegmann-Burns M, Goldblum D: Effects of daunorubicin, mitomycin C, azathioprine and cyclosporin A on human retinal pigmented epithelial, corneal endothelial and conjunctival cell lines. Graefes Arch Clin Exp Ophthalmol 2006;244:382-389.
18. Seki Y, Toba K, Fuse I, Sato N, Niwano H, Takahashi H, Tanabe N, Aizawa Y: In vitro effect of cyclosporin A, mitomycin C and prednisolone on cell kinetics in cultured human umbilical vein endothelial cells. Thromb Res 2005;115:219-228.
19. Markovic S, Raab M, Daxecker H, Griesmacher A, Karimi A, Müller MM: In vitro effects of cyclosporin A on the expression of adhesion molecules on human umbilical vein endothelial cells. Clin Chim Acta 2002;316:25-31.
20. Maksymowicz M, Lukomska B, Ziolkowska A, Janczewska S, Cybulska E, Olszewski WL: Cyclosporin A decreases lymphocyte migration to the heart allograft through suppression of their L-selectin expression. Ann Transplant 1998;3:34-36.
21. Rafiee P, Johnson CP, Li MS, Ogawa H, Heidemann J, Fisher PJ, Lamirand TH, Otterson MF, Wilson KT, Binion DG: Cyclosporine A enhances leukocyte binding by human intestinal microvascular endothelial cells through inhibition of p38 MAPK and iNOS: paradoxical proinflammatory effect on the microvascular endothelium. J Biol Chem 2002;277:35605-35615.
22. Karlsson H, Nassberger L: FK506 suppresses the mitogen-induced increase in lymphocyte adhesiveness to endothelial cells, but does not affect endothelial cell activation in response to inflammatory stimuli. Transplantation 1997;64:1217-1220.
23. Mancini D, Pinney S, Burkhoff D, LaManca J, Itescu S, Burke E, Edwards N, Oz M, Marks AR: Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003;108:48-53.
24. Schreml S, Lehle K, Birnbaum DE, Preuner JG: mTOR-inhibitors simultaneously inhibit proliferation and basal IL-6 synthesis of human coronary artery endothelial cells. Int Immunopharmacol 2007;7:781-791.
25. Pinney SP, Mancini D: Cardiac allograft vasculopathy: advances in understanding its pathophysiology, prevention, and treatment. Curr Opin Cardiol 2004;19:170-176.
26. Valantine HA: Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant 'atheroma'. Transplantation 2003;76:891-899.
27. Lehle K, Birnbaum DE, Preuner JG: Predominant inhibition of interleukin-6 synthesis in patient-specific endothelial cells by mTOR inhibitors below a concentration range where cell proliferation is affected and mitotic arrest takes place. Transplant Proc 2005;37:159-161.
28. Riesterer O, Zingg D, Hummerjohann J, Bodis S, Pruschy M: Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells. Oncogene 2004;23:4624-4635.
29. Sugatani T, Hruska KA: Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem 2005;280:3583-3589.
30. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, Virmani R: Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99:44-52.
31. Grewe PH, Deneke T, Machraoui A, Barmeyer J, Muller KM: Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol 2000;35:157-163.
32. Wildhirt SM, Schulze C, Conrad N, Bauernschmitt R, Lange R, von Scheidt W: Persistently increased systemic, but not cardiac-specific, adhesion molecule expression and coronary endothelial dysfunction in human cardiac allografts. J Thorac Cardiovasc Surg 2005;130:1175.
33. Schmid C, Heemann U, Azuma H, Tilney NL: Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts. Transplantation 1995;60:729-733.
34. Bestard O, Cruzado JM, Grinyo JM: Calcineurin-inhibitor-sparing immunosuppressive protocols. Transplant Proc 2005;37:3729-3732.
35. Merville P: Combating chronic renal allograft dysfunction: optimal immunosuppressive regimens. Drugs 2005;65:615-631.
36. Stins MF, Gilles F, Kim KS: Selective expression of adhesion molecules on human brain microvascular endothelial cells. J Neuroimmunol 1997;76:81-90.
37. Haubitz M, Brunkhorst M: Influence of a novel rapamycin analogon SDZ RAD on endothelial tissue factor and adhesion molecule expression. Transplant Proc 2002;34:1124-1126.
38. Wood SC, Bushar G, Tesfamariam B: Inhibition of mammalian target of rapamycin modulates expression of adhesion molecules in endothelial cells. Toxicol Lett 2006;165:242-249.
39. Sotiriou SN, Orlova VV, Al-Fakhri N, Ihanus E, Economopoulou M, Isermann B, Bdeir K, Nawroth PP, Preissner KT, Gahmberg CG, Koschinsky ML, Chavakis T: Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J 2006;20:559-561.